Drug Trial Radar · NCT07225569
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Sep 22, 2027
Study completion Nov 19, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis suppurativa. The purpose of this study is to assess the efficacy and safety of two doses of SAR445399 compared with placebo in adult participants with moderate to severe hidradenitis suppurativa. The study duration (per participant) will be up to 46 weeks with a total of 16 visits. The treatment duration will be 32 weeks which includes 16-week double-blinded initial treatment period and a 16-week treatment-blinded extension period.
Conditions
- Hidradenitis Suppurativa
Interventions
SAR445399Drug
Pharmaceutical form: Solution for injection -Route of administration: Injection
PlaceboDrug
Pharmaceutical form: Solution for injection -Route of administration: Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants achieving Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)Time frame: Up to Week 16
Locations
86 sites in 15 countries. Site status is shown where the registry gives one.
Scottsdale Clinical Trials- Site Number : 8400006
Scottsdale, Arizona · Recruiting
Carbon Health - North Hollywood - NoHo West- Site Number : 8400017
North Hollywood, California · Active not recruiting
Encore Medical Research of Boynton Beach- Site Number : 8400005
Boynton Beach, Florida · Recruiting
FXM Clinical Research - Fort Lauderdale- Site Number : 8400013
Fort Lauderdale, Florida · Recruiting
Alliance for Multispeciality Research - Fort Myers- Site Number : 8400007
Fort Myers, Florida · Recruiting
Encore Medical Research - Hollywood- Site Number : 8400004
Hollywood, Florida · Recruiting
Fxm Clinical Research/Fax Pharma Clinical Research- Site Number : 8400014
Miami, Florida · Recruiting
Florida International Research Center- Site Number : 8400002
Miami, Florida · Recruiting
Florida Research Center- Site Number : 8400009
Miami, Florida · Recruiting
Advanced Clinical Research Institute- Site Number : 8400021
Tampa, Florida · Recruiting
Cleaver Medical Group Dermatology- Site Number : 8400008
Cumming, Georgia · Recruiting
First Georgia Physician Group- Site Number : 8400033
Fayetteville, Georgia · Recruiting
NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8400019
Skokie, Illinois · Recruiting
Deaconess Clinic - Downtown Fourth Street- Site Number : 8400029
Evansville, Indiana · Recruiting
Dermatology Specialists Research (DS Research) - Kentucky- Site Number : 8400026
Louisville, Kentucky · Recruiting
Beth Israel Deaconess Medical Center - Boston- Site Number : 8400001
Boston, Massachusetts · Recruiting
University Health Dermatology- Site Number : 8400018
Kansas City, Missouri · Recruiting
Equity Medical (LLC)- Site Number : 8400010
The Bronx, New York · Recruiting
Essential Medical Research- Site Number : 8400015
Tulsa, Oklahoma · Recruiting
Elligo Health Research/The Woodlands Dermatology Associates- Site Number : 8400020
The Woodlands, Texas · Recruiting
Virginia Dermatology & Skin Cancer Center- Site Number : 8400024
Norfolk, Virginia · Recruiting
Investigational Site Number : 0320001
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320002
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320003
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0360001
Sydney, New South Wales, Australia · Recruiting
Investigational Site Number : 0360003
Woodville, South Australia, Australia · Recruiting
Investigational Site Number : 0360002
South Perth, Western Australia, Australia · Recruiting
Investigational Site Number : 0560002
Brussels, Belgium · Recruiting
Investigational Site Number : 0560001
Ghent, Belgium · Recruiting
Investigational Site Number : 0560004
Liège, Belgium · Recruiting
Hospital Israelita Albert Einstein- Site Number : 0760004
São Paulo, Brazil · Recruiting
Centro de Pesquisas da Clínica IBIS- Site Number : 0760001
Salvador, Estado de Bahia, Brazil · Recruiting
Hospital das Clinicas da UNICAMP- Site Number : 0760002
Campinas, São Paulo, Brazil · Recruiting
Investigational Site Number : 1240016
Winnipeg, Manitoba, Canada · Recruiting
Investigational Site Number : 1240015
Mississauga, Ontario, Canada · Recruiting
Investigational Site Number : 1240001
Richmond Hill, Ontario, Canada · Recruiting
Investigational Site Number : 1240014
Toronto, Ontario, Canada · Recruiting
Investigational Site Number : 1240010
Montreal, Quebec, Canada · Recruiting
Investigational Site Number : 1240002
Sherbrooke, Quebec, Canada · Recruiting
Investigational Site Number : 1240013
Regina, Saskatchewan, Canada · Recruiting
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.